Overall Survival (OS), progression-free survival (PFS), and objective response (OR) to treatment by abnormality
Abnormality . | N . | Median OS with abnormality, mo (95% Cl) . | Median OS without abnormality, mo (95% Cl) . | P . | Median PFS with abnormality, mo (95% Cl) . | Median PFS without abnormality, mo (95% Cl) . | P . | OR* with abnormality, n (%) . | OR* without abnormality, n (%) . | P . | 5-y OS rate with abnormality, % . | 5-y OS rate without abnormality, % . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| t(4;14)(p16;q32) | 332 | 26 (21-33) | 45 (39-50) | <.001 | 17 (13-21) | 31 (28-34) | <.001 | 26 (62) | 197 (69) | .38 | 10 | 32 |
| t(14;16)(q32;q23) | 323 | 16 (13-22) | 41 (37-48) | .003 | 9 (6-13) | 30 (27-32) | .003 | 8 (53) | 204 (68) | .27 | 13 | 29 |
| t(11;14)(q13;q32) | 336 | 50 (37-60) | 39 (36-44) | .332 | 33 (28-45) | 27 (25-31) | .590 | 39 (78) | 187 (67) | .14 | 38 | 28 |
| Deletion 17p13 | 345 | 23 (20-36) | 44 (39-49) | .005 | 17 (11-24) | 30 (27-33) | .051 | 25 (68) | 208 (69) | .85 | 16 | 31 |
| Δ13 | 325 | 35 (29-41) | 51 (41-57) | .028 | 25 (21-29) | 33 (30-37) | .030 | 109 (63) | 108 (74) | .04 | 22 | 38 |
Abnormality . | N . | Median OS with abnormality, mo (95% Cl) . | Median OS without abnormality, mo (95% Cl) . | P . | Median PFS with abnormality, mo (95% Cl) . | Median PFS without abnormality, mo (95% Cl) . | P . | OR* with abnormality, n (%) . | OR* without abnormality, n (%) . | P . | 5-y OS rate with abnormality, % . | 5-y OS rate without abnormality, % . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| t(4;14)(p16;q32) | 332 | 26 (21-33) | 45 (39-50) | <.001 | 17 (13-21) | 31 (28-34) | <.001 | 26 (62) | 197 (69) | .38 | 10 | 32 |
| t(14;16)(q32;q23) | 323 | 16 (13-22) | 41 (37-48) | .003 | 9 (6-13) | 30 (27-32) | .003 | 8 (53) | 204 (68) | .27 | 13 | 29 |
| t(11;14)(q13;q32) | 336 | 50 (37-60) | 39 (36-44) | .332 | 33 (28-45) | 27 (25-31) | .590 | 39 (78) | 187 (67) | .14 | 38 | 28 |
| Deletion 17p13 | 345 | 23 (20-36) | 44 (39-49) | .005 | 17 (11-24) | 30 (27-33) | .051 | 25 (68) | 208 (69) | .85 | 16 | 31 |
| Δ13 | 325 | 35 (29-41) | 51 (41-57) | .028 | 25 (21-29) | 33 (30-37) | .030 | 109 (63) | 108 (74) | .04 | 22 | 38 |
The number of patients evaluable for response may be slightly smaller than N given in column 2.